CA-125

CA-125, also known as CA125, is an abbreviation for cancer antigen 125. CA-125 is a tumor marker or biomarker that may be elevated in the blood of some people with specific types of cancers. CA-125 is a mucinous glycoprotein and the product of the MUC16 gene.

Additional recommended knowledge

Recognize and detect the effects of electrostatic charges on your balance

How to quickly check pipettes?

How to ensure accurate weighing results every day?

Specificity and sensitivity

It is best known as a marker for ovarian cancer, but it may also be elevated in other malignant cancers, including those originating in the endometrium, fallopian tubes, lungs, breast and gastrointestinal tract.

CA125 may also be elevated in a number of relatively benign conditions, such as endometriosis,^[1] several diseases of the ovary, and pregnancy.^[2] It also tends to be elevated in the presence of any inflammatory condition in the abdominal area, both cancerous and benign.

Thus, CA-125 is not perfectly specific for cancer nor is it perfectly sensitive since not every patient with cancer will have elevated levels of CA-125 in the blood.^[3] For example, 79% of all ovarian cancers are positive for CA125, whereas the remainder do not express this antigen at all.^{[citation needed]}

Use

CA-125 is clinically approved for following the response to treatment and predicting prognosis after treatment. It is especially useful for detecting the recurrence of ovarian cancer. Its potential role for the early detection of ovarian cancer is controversial and has not yet been adopted for widespread screening efforts in asymptomatic women. The key problems in using the CA-125 test as a screening tool are its lack of specificity and its inability to detect early stage cancers. An operation would be necessary to confirm that a woman with elevated CA-125 has ovarian cancer, with the associated risk of death from major surgery. In addition, even if cancer was confirmed in such circumstances, it usually would be at an advanced stage where therapy is less effective. The goal of many cancer biologists is to develop a test that would be employed to diagnose ovarian cancer at an early stage, when the effects of therapeutic interventions are optimal.

History

CA-125 was initially detected using the monoclonal antibody designated OC125. Dr. Robert Bast and his research team first isolated this monoclonal antibody in 1981.^[4]

Ranges in ovarian cancer

While this test is not generally regarded as useful for large scale screening by the medical community, a high value may be an indication that the woman should receive further diagnostic screening or treatment. Normal values range from 0 to 35 (u/mL). Elevated levels in post-menopausal women are usually an indication that further screening is necessary. In pre-menopausal women, the test is less reliable as values are often elevated due to a number of non-cancerous causes, and a value above 35 is not necessarily a cause for concern.

References

1. ^ Bagan P, Berna P, Assouad J, Hupertan V, Le Pimpec Barthes F, Riquet M (2007). "Value of Ca 125 for diagnosis of pleural endometriosis in women with recurrent pneumothorax". doi:10.1183/09031936.00094206. PMID 17804443.
2. ^ Sarandakou A, Protonotariou E, Rizos D (2007). "Tumor markers in biological fluids associated with pregnancy". Critical reviews in clinical laboratory sciences 44 (2): 151–78. doi:10.1080/10408360601003143. PMID 17364691.
3. ^ Screening Asymptomatic Women for Ovarian Cancer: American College of Preventive Medicine Practice Policy. Retrieved on 2007-09-29.
4. ^ Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC (1981). "Reactivity of a monoclonal antibody with human ovarian carcinoma". J. Clin. Invest. 68 (5): 1331–7. PMID 7028788.

See also

• CA-125 blood test urban legend at snopes.com